In August 2025, the international trade team of Shanghai Kinetic Medical Co., Ltd. (hereinafter referred to as "Kinetic"), led by Mr. Liu Wei, Deputy General Manager and Head of International Business, conducted a business visit to its distributor in Japan. As a leading enterprise in China's orthopedic minimally invasive intervention field, Kinetic has always focused on the R&D and manufacturing of medical devices. This trip marked not only the first offline meeting between the two parties in Japan since the pandemic, but also served as a strategic exchange following the comprehensive upgrade of Kinetic's product portfolio, signaling a new stage of the bilateral cooperation. 

During the visit, Mr. Noguchi, Chairman of the Japanese distributor, extended a warm welcome to the Kinetic delegation and provided a detailed overview of the distributor’s current operations, sales performance, and mid-to-long-term development strategy. Having partnered with Kinetic since 2017, the distributor has acted as a core bridge for introducing Kinetic's products to the local market.

Accompanied by the distributor, the Kinetic team visited several authoritative medical institutions in Tokyo, engaging in in-depth discussions with clinical experts regarding product applications and technical features. Japanese surgeons spoke highly of Kinetic's 2.0 Version PKP (Kyphoplasty) System, highlighting the following advantages:

l Ease of Use‌: Significantly reduces the preoperative preparation time and simplifies the procedures.

l ‌High Stability‌: Demonstrates reliable long-term performance.

l Superior Compliant Balloon Catheter‌: The KMC Balloon Catheter adapts to diverse bone structures and vertebral morphologies, providing stable and controllable expansion force that effectively reduces surgical risks. 

It is noteworthy that in complex cases such as vertebral tumors, Japanese surgeons show a distinct preference for Kinetic’s products. At some of the hospitals visited, Kinetic’s adoption rate in kyphoplasty procedures has reached as high as 80%, reflecting excellent market acceptance.

In closing, Mr. Liu Wei emphasized that the Japanese distributor has been a core partner in Kinetic’s global strategy since 2017, and it’s success in high-end markets strongly proves the international competitiveness of Kinetic's products.  He expressed his hope that this visit would further deepen collaboration, expand cooperation areas, and advance shared strategic goals. Kinetic remains committed to innovation, delivering high-quality products and services to protect the health of patients worldwide, and working closely with partners to embark on a new journey of mutual benefit and win-win outcomes.